Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05306574 · ClinicalTrials.gov registry record · Phase 3
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
A Phase 3 study, sponsored by Vor Biopharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT05306574: Clinical Trial Phase 3 study, sponsored by Vor Biopharma.
NCT05306574 is a Phase 3 study that was terminated before completion, run by Vor Biopharma. The registered enrollment target is 91 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05306574, a Phase 3 study, was terminated before completion, sponsored by Vor Biopharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
Primary Outcome
Proportion of subjects achieving an SLE Responder Index (SRI-4) response at Week 52
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Telitacicept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2022-06-20 |
| Est. Completion | 2025-01-06 |
| Phase | Phase 3 |
Why NCT05306574 stopped before completion
NCT05306574 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05306574 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05306574 about?
NCT05306574 is a clinical study titled "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)". The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
What is the current status of trial NCT05306574?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2022-06-20. Estimated completion is 2025-01-06.
What interventions are being tested in trial NCT05306574?
The interventions under investigation include: Placebo (BIOLOGICAL), Telitacicept (BIOLOGICAL).
Who is sponsoring clinical trial NCT05306574?
This trial is sponsored by Vor Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05306574's enrollment target sits among peer trials
91 1724th of 2000 higher than 277 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI